Brought to you by 
Initial public offering nets $80.3mm for aTyr Pharma
13 May 2015
Executive Summary
Just two months after closing a $76mm Series E round, aTyr Pharma Inc. (physiocrine-based therapies for rare diseases) went public on Nasdaq selling 6.2mm common shares (including the overallotment) at $14. The IPO, which netted $80.3mm, priced at the mid-range of aTyr's $13-15 goal. The company had planned to offer 5.4mm shares.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Initial public offering nets $80.3mm for aTyr Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice